摘要
目的研究阿糖胞苷(Ara-C),阿克拉霉素(Acla)联合粒细胞集落刺激因子(G-CSF)治疗复发急性髓系白血病的临床疗效。方法将我院2008年1月至2009年3月收治的47例复发急性髓系白血病患者随机分为A组24例和B组23例,A组采用Ara-C、Acla联合G-CSF(CAG方案)治疗,B组采用Acla,足叶乙甙(VP16)和Ara-C(AEA方案)治疗。结果A、B两组的疗效无显著性差异,但A组的不良反应发生率低于B组。结论Ara-C、Acla联合G-CSF治疗复发急性髓系白血病获得较佳疗效,且不良反应少,值得临床关注。
Objective To study on the effect of acute myeloid leukemia treated by Ara-C,Acla combined with G-CSF.Methods From January 2008 to March 2009 in our hospital,the 47 patients with acute myeloid leukemia were randomly divided into A group（n=24）and B group（n=23）.The A group treated by Ara-C,Acla combined with G-CSF（CAG regimen）,and the B group treated by Acla,VP16 combined with Ara-C（AEA regimen）.Results The efficacy of the two groups had no significant difference,but the incidence of adverse reactions of the A group is lower than that of the B group.Conclusion Ara-C,Acla combined with G-CSF has satisfactory effects and fewer adverse events on acute myeloid leukemia patients,it is worth spreading.
出处
《中国实用医药》
2010年第7期6-7,共2页
China Practical Medicine
